Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of CKD-393 vs Co-administration of CKD-501, D759, and H053 in Healthy Adults
NCT04768673Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Mar 2021
- Primary completion
- Apr 2021
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-393 in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum Plasma Concentration at 48 hours and Area Under the Curve to Last Quantifiable Concentration at 48 hours. Started Mar 2021; status: completed.
02
Drugs
CKD-393
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04768673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04768673.